A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810) ADMINISTERED INTRALESIONALLY FOR PATIENTS WITH RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Cutaneous Squamous Cell Carcinoma
  • Age: Between 18 - 89 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) History of recurrent resectable CSCC that satisfies either of the following conditions: -At least 1 prior CSCC in the head and neck that was surgically removed within 3 years prior to date of consent, now with a recurrent CSCC in the head and neck area that will be the index lesion for the study and is .0 cm and <2.0 cm (longest diameter) -At least 2 prior CSCCs of trunk or extremity that were surgically removed within 3 years prior to date of consent, now with a recurrent CSCC of trunk or extremity that will be the index lesion for the study (any anatomic location) and is >1.0 cm and <2.0 cm (longest diameter).

You may not be eligible for this study if the following are true:

  • iConnect Exclusion Criteria: 1) Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs). 2) Prior treatment with an agent that blocks the programmed cell death 1 (PD-1)/ programmed cell death 1 ligand (PD-L1) pathway.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.